Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 26, Issue 6, 1998, Pages 717-733

  Levasseur, Laurence M ^a   Faessel, Hélène ^a   Slocum, Harry K ^a   Greco, William R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Hill model; Nonlinear regression; Parameter; Power model; Sulforhodamine B; Weighting function

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL; DATA ANALYSIS; HUMAN; HUMAN CELL; NONLINEAR SYSTEM; OVARY CARCINOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL DIVISION; HUMANS; MODELS, BIOLOGICAL; TUMOR CELLS, CULTURED;

EID: 0032465812     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020755124451     Document Type: Article

References (25)

1. L. Levasseur, H. Faessel, H. K. Slocum, and W. R. Greco. Precision and pattern in 96-well plate cell growth experiments. Proc. Biopharm. Sect. Am. Statist. Assoc. pp. 227-232 (1995).
2. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112 (1990).
3. K. Crickard, M. J. Niedbala, U. Crickard, M. Yoonessi, A. A. Sandberg, K. Okuyama, R. J. Bernacki, and S. K. Satchidanand. Characterization of human ovarian and endometrial carcinoma cell lines established on extracellular matrix. Gynecol. Oncol. 32:163-173 (1989).
4. A. M. Rogan, T. C. Hamilton, R. C. Young, R. W. Klecker, Jr., and R. F. Ozols. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224:994-996 (1984).
5. M. A. Alaoui Jamali, M. B. Yin, A. Mazzoni, I. Bankusli, and Y. M. Rustum. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: Modulation by the tiapamil analog RO11-2933. Cancer Chemother. Pharmacol. 25:77-83 (1989).
6. D. Z. D'Argenio and A. Schumitzky. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software, Biomedical Simulations Resource, Los Angeles, 1997.
7. J. P. Parsons, L. M. Levasseur, H. Faessel, H. K. Slocum, L. A. Khinkis, and W. R. Greco. Computer software for assessing in vitro anticancer multiple-agent combined-action: The search for synergy. Proc. Ann. Meet. Am. Assoc. Cancer Res. 38:A2131 (1997).
8. M. Davidian and R. J. Carroll. Variance function estimation. J. Am. Statist. Assoc. 82:1079-1091 (1987).
9. D. J. Finney and P. Phillips. The form and estimation of a variance function, with particular reference to radioimmunoassay. Appl. Statist. 26:312-320 (1977).
10. B. Mannervik, I. Jakobson, and M. Warholm. Error structure as a function of substrate and inhibitor concentration in enzyme kinetic experiments. Biochem. J. 235:797-804 (1986).
11. S. L. Beal and L. B. Sheiner. Heteroscedastic nonlinear regression. Technometrics 30:327-338 (1988).
12. D. Rodbard, R. H. Lenox, H. L. Wray, and D. Ramseth. Statistical characterization of the random errors in the radioimmunoassay dose-response variable. Clin. Chem. 22:350-358 (1976).
13. N. H. Holford and L. B. Sheiner. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit. Rev. Bioeng. 5:273-322 (1981).
14. A. V. Hill. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. 40:iv-vii (1910).
15. L. F. Shackell, W. Williamson, M. M. Deitchman, G. M. Katzman, and B. S. Kleinman. The relation of dosage to effect. J. Pharmacol. 24:53 (1924).
16. N. H. Holford and L. B. Sheiner. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokin. 6:429-453 (1981).
17. T. A. J. Ryan and B. L. Joiner. Normal Probability Plots and Tests for Normality. Technical Report, Statistics Department, Pennsylvania State University, 1976.
18. L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. Simon, S. Tosini, P. Skehan, D. A. Scudiero, A. Monks, and M. R. Boyd. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82:1113-1118 (1990).
19. B. T. Hill and R. D. Whelan. Assessments of the sensitivities of cultured human neuroblastoma cells to anti-tumour drugs. Pediat. Res. 15:1117-1122 (1981).
20. L. M. Levasseur, W. R. Greco, Y. M. Rustum, and H. K. Slocum. Combined-action of paclitaxel and cisplatin against wild-type and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 40:495-505 (1997).
21. H. M. Faessel, H. K. Slocum, R. C. Jackson, T. J. Boritzki, Y. M. Rustum, M. G. Nair, and W. R. Greco. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: The critical role of polyglutamylation. Cancer Res. 58:3036-3050 (1998).
22. L. M. Levasseur, H. K. Slocum, Y. M. Rustum, and W. R. Greco. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res. 58:5749-5761 (1998).
23. D. Rodbard and G. R. Frazier. Statistical analysis of radioligand assay data. J. Immunol. Meth. 37:3-22 (1975).
24. A. Cornish-Bowden and L. Endrenyi. Fitting of enzyme kinetic data without prior knowledge of weights. Biochem. J. 193:1005-1008 (1981).
25. H. K. Slocum, G. H. Heppner, and Y. M. Rustum. Cellular heterogeneity of human tumors: Implications for understanding and treating cancer. Biol. Respon. Cancer 4:183-248 (1985).